CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S74-S75
DOI: 10.1055/s-0039-1686012
Abstracts
Oncology

Laryngectomy survey

A Knopf
1   HNO Klinik, Klinikum rechts der Isar, München, München
,
S Laban
2   Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinik Ulm, Ulm
,
TK Hoffmann
2   Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinik Ulm, Ulm
,
C Jacobi
3   HNO Klinik, Klinikum rechts der Isar, München/linik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität München, München
,
A Berghaus
4   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität München, München
,
W Föhringer
5   Zentrum für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Gießen, Gießen
,
JP Klußmann
6   Zentrum für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Gießen/Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Uniklinik Köln, Gießen/Köln
,
J Pfeiffer
7   Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Freiburg, Freiburg
,
R Laszig
7   Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Freiburg, Freiburg
,
H Bier
1   HNO Klinik, Klinikum rechts der Isar, München, München
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction:

    There is an inherent focus on larynx-preserving-therapy in pharyngeal and laryngeal cancer. In literature, classical laryng(opharnyg)ectomy (LPE) becomes less important. However, recent data demonstrates a stable LPE rate over the last decades.

    Methods:

    Five centers included 783 patients (2004 – 2014) who underwent LPE. Data were compared with oncological parameters of 2,307 patients who suffered from primary hypopharyngeal and laryngeal cancer and underwent chemo-/radiation (C/RT), larynx-preserving-surgery (LpreS), or LPE.

    Results:

    There was a stable LPE rate in the analyzed period. LPE was done as primary therapy in 80% of patients and in 20% due to recurrence. Analysis of the overall survival (OS) in LpreS vs. C/RT demonstrated comparable OS in T1/2N0 supraglottic, glottic, and hypopharyngeal cancer (p = 0.63; p = 0.26; p = 0.61). Nodal-positive or ≥T3/4N0 supraglottic/hypopharyngeal cancer showed significantly better OS after LpreS/LPE than C/RT (p < 0.0001 – 0.04). LPE was associated with significantly better OS in ≥T3N0 glottic cancer when compared with C/RT (p < 0.0001 – 0.001). LPE due to recurrent disease did not result in reduced OS compared to primary LPE exclusively in glottic cancer.

    Conclusions:

    LpreS and C/RT can be applied in T1/2N0 cancer. We have to recognize that tumor recurrence after larynx-preserving therapy will reduce OS in hypopharyngeal and supraglottic cancer. Surgical approaches should be preferred in nodal-positive and ≥T3 cancer.


    #
    Prof. Dr. Andreas Knopf
    HNO Klinik, Klinikum rechts der Isar, München,
    Ismaninger 22, 81675
    München

    Publication History

    Publication Date:
    23 April 2019 (online)

    © 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York